No Survival Advantage for ADT Plus Radiation
There's a saying that less is more. For men with intermediate-risk prostate cancer weighing hormone therapy on top of radiation, that phrase turns out to be more than a proverb. Five-year results from a landmark 1,492-patient trial found better cancer control in the combined group, no survival difference, and a real cost in side effects. keep reading
